Neuronetics, Inc. (STIM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d226320dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 SEPARATION AGREEMENT This Separation Agreement (the “ Agreement ”) is entered into by and between NEURONETICS, INC., a Delaware corporation, and W. ANDREW MACAN (“ Executive ”) (together, “ the Parties ”) to set forth their
How this was made
The 30-second read
Why it matters
The main tradable element is the explicit severance/retention payout ($231,750 gross) and RSU vesting timing on the separation date (Aug. 15, 2026). No new guidance, trial results, or strategic transactions are disclosed in the provided text.
Market read
Traders may treat this as a low-impact governance/transition event with limited fundamental implications, unless follow-on disclosures emerge.
What to watch
The filing includes garden leave and continued compensation through the separation date, which may reduce near-term disruption risk versus a sudden exit.
Background
The filing is an SEC Form 8-K (Item 5.02) describing a separation agreement tied to termination of employment without cause under existing restrictive covenant and severance arrangements.
Ticker impact
Neuronetics disclosed a separation agreement for an executive, including a $231,750 retention bonus payout and RSUs vesting on Aug. 15, 2026.
Low likelihood of a sustained move; any reaction is likely limited to event-driven positioning around the filing.
The 8-K is an Item 5.02 executive departure/separation agreement with specified severance/vesting mechanics, but it does not disclose new clinical, financial, or strategic guidance.
Market effects
Limited read-across to biotech sector operations; this is company-specific executive compensation/transition language.
No clear regional market linkage.
Minimal global relevance; filing is administrative rather than strategic.
Counterpoint
The disclosed termination without cause could signal internal governance or performance issues, which some traders may overreact to despite the lack of stated operational impact.
Key entities
- issuerNeuronetics, Inc.
Subject of the SEC 8-K, disclosed executive separation and related compensatory arrangements.
- executiveW. Andrew Macan
Executive covered by the separation agreement; employment ends Aug. 15, 2026, with specified payout and vesting mechanics.
